{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-169513","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.986618+00:00","generated_at":"2026-06-13T21:43:26.084137+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Cytek Biosciences shareholders elect three Class II directors and approve say-on-pay","bullets":["All three director nominees (Jack Ball, Vera Imper, Ming Yan) elected with 55.9M–56.9M votes for; broker non-votes 25.6M.","Advisory vote on 2022 executive compensation passed with 57.4M for, 1.4M against, 0.8M abstentions.","Advisory vote on frequency of say-on-pay: one-year option received 58.6M votes; two- and three-year options negligible.","Ratification of Deloitte & Touche as auditor for FY2023 approved with 84.9M for, 11k against.","Approximately 63% of outstanding shares (85.2M of 135.7M) represented at the 2023 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-169513","json":"https://secwatch.observer/filing/0001193125-23-169513.json","markdown":"https://secwatch.observer/filing/0001193125-23-169513.md","text":"https://secwatch.observer/filing/0001193125-23-169513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/d483871d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T21:43:26.084137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"183df3ceb2edc8c1e0f177861f17d7fab1f6836d","claim":"Cytek Biosciences, Inc. shareholders approved Frequency of Stockholder Vote on Executive Compensation (advisory vote) at the 2023-06-14 meeting.","evidence_excerpt":"3. Frequency of Stockholder Vote on Executive Compensation. On an advisory basis, a one-year frequency of future advisory votes on the compensation of the Company’s named executive officers was approved based on the following results of voting: One Year Two Years Three Years Abstentions Broker Non-Votes 58,649,562 109,046 165,909 686,914 25,604,540","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"4776b289af188b6f6aa943f143701c008efae020","claim":"Cytek Biosciences, Inc. shareholders approved Executive Compensation (advisory vote) at the 2023-06-14 meeting.","evidence_excerpt":"2. Executive Compensation. On an advisory basis, compensation paid to the Company’s named executive officers for the year ended December 31, 2022 was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 57,420,396 1,390,622 800,413 25,604,540","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"75434b5c95875738cfdc2c2f94f6c8a66571768c","claim":"Cytek Biosciences, Inc. shareholders approved Election of Class II Directors at the 2023-06-14 meeting.","evidence_excerpt":"1. Election of Class II Directors. Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2026 annual meeting of stockholders or until his or her successor has been duly elected and qualified or his or her earlier death, resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Jack Ball 55,857,084 3,754,347 25,604,540 Vera Imper, Ph.D. 49,090,622 10,520,809 25,604,540 Ming Yan, Ph.D. 56,925,027 2,686,404 25,604,540","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"d6165ce49ed71dc319c56b3cf24b96e0d643dded","claim":"Cytek Biosciences, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-14 meeting.","evidence_excerpt":"4. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 84,894,550 11,239 310,182 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523169513/0001193125-23-169513-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}